Filtered By:
Management: Marketing

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 200 results found since Jan 2013.

Hemorrhagic stroke and new oral anticoagulants.
Abstract The recent release of new oral anticoagulants (NOAC) raises the question of the management of intracranial hemorrhage occurring during treatment with these molecules. Dabigatran, rivaroxaban and apixaban have different pharmacological characteristics that physicians need to know to adjust their prescription to each patient. Studies of efficacy and safety prior to the marketing of these molecules showed a decreased risk of intracranial hemorrhage compared with vitamin K antagonists. However, no reliable data are available regarding the prognosis of these hemorrhages occurring during NOAC treatment. In addi...
Source: Annales Francaises d'Anesthesie et de Reanimation - October 1, 2014 Category: Anesthesiology Authors: Derlon V, Corbonnois G, Martin M, Toussaint-Hacquard M, Audibert G Tags: Ann Fr Anesth Reanim Source Type: research

Thrombolysis in acute ischaemic stroke - time for a rethink?
In the US the licence, or marketing authorisation, for alteplase is limited to 0-3 hours after onset of stroke, but some other countries - including the UK and Australia - have extended the licence to 4.5 hours. In an analysis article on thebmj.com Brian Alper, vice president of evidence based medicine research and development at Dynamed, and colleagues, interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours. Read their full analysis: http://www.bmj.com/content/350/bmj.h1075
Source: The BMJ Podcast - March 18, 2015 Category: Journals (General) Authors: BMJ talk medicine Source Type: podcasts

German giant Boehringer Ingelheim battles India's Gennova Biopharma over stroke treatment
Gennova recently secured marketing authorisation of tenectaplase for stroke patients in India, the first such use of the drug anywhere in the world.
Source: The Economic Times Healthcare and Biotech News - August 17, 2016 Category: Pharmaceuticals Source Type: news

FDA allows marketing of clot retrieval devices to reduce disability in stroke patients
The U.S. Food and Drug Administration today allowed marketing of two Trevo clot retrieval devices as an initial therapy for strokes due to blood clots (ischemic) to reduce paralysis, speech difficulties and other stroke disabilities. These devices should be used within six hours of symptom onset and only following treatment with a clot-dissolving drug (tissue plasminogen activator or t-PA), which needs to be given within three hours of symptom onset.
Source: Food and Drug Administration - September 2, 2016 Category: American Health Source Type: news

Keystone Heart, Venus Medtech ink Asian TAVR stroke partnership deal
Keystone Heart and Chinese heart valve maker Venus Medtech said today they inked a partnership deal covering China and other Asian markets. Through the deal, the companies will provide Venus Medtech’s transcatheter aortic valve replacement system along with Keystone’s TriGuard cerebral embolic protection device. TriGuard is a cerebral embolic protection device designed to reduce the amount of embolic material entering blood circulation to the brain during TAVR procedures, by allowing blood to pass through while catching potentially dangerous embolic debris. “Providing brain protection for every TAVR pat...
Source: Mass Device - March 2, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Replacement Heart Valves Keystone Heart Venus Medtech Source Type: news

Criteria for the choice of anticoagulant therapy for the prevention of stroke in patients with atrial fibrillation early after the marketing of direct oral anticoagulants in Italy.
PMID: 28476324 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - May 2, 2017 Category: Internal Medicine Authors: Marzona I, Roncaglioni MC, Avanzini F, Franzosi MG, Moia M, members of an ad hoc study group Tags: Eur J Intern Med Source Type: research

Silk Road Medical Appoints World Class Stroke Prevention Champion to Serve as Vice President, Medical Affairs and Professional Education
Tammy Leitsinger to spearhead global physician education and peer-to-peer training for rapidly growing Trans Carotid Artery Revascularization (TCAR) procedure SUNNYVALE, Calif., Oct. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Silk Road Medic... Devices, Neurology, Personnel Silk Road Medical, ENROUTE, TransCarotid Artery Revascularization, stroke
Source: HSMN NewsFeed - October 11, 2017 Category: Pharmaceuticals Source Type: news

FDA permits marketing of clinical decision support software for alerting providers of a potential stroke in patients
Source: Food and Drug Administration - February 13, 2018 Category: American Health Source Type: news

FDA Permits Marketing of Clinical Decision Support Software for Alerting Providers of a Potential Stroke in Patients
Today, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.
Source: eHealth News EU - February 13, 2018 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

SanBio and Teijin to Terminate Licensing Agreement regarding SB623 for Stroke Treatment
Tokyo, Japan, February 14, 2018 --(Healthcare Sales & Marketing Network)-- SanBio, Inc. and Teijin Limited jointly announced today that they would terminate the exclusive licensing agreement signed in 2009 regarding the development and marketing of SB623 f... Biopharmaceuticals, Neurology, Licensing Teijin Limited, SanBio Inc, stroke
Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news

Viz.ai ’s stroke-detecting CDS app receives FDA nod
The FDA announced yesterday that it will permit marketing of Viz.ai ’s Contact, a clinical decision support (CDS) tool that analyzes CT results and highlights cases that may have experienced a stroke.
Source: mobihealthnews - February 14, 2018 Category: Information Technology Source Type: news

Omega-3 no protection against heart attack or strokes, say scientists
Supplements do not offer cardiovascular benefits, researchers conclude from trials involving 112,000 peopleThe widespread belief that taking omega-3 capsules will help protect you from a heart attack, stroke or early death is wrong, according to a large and comprehensive review of the evidence.Thousands of people take omega-3 supplements regularly and for years. The belief that it protects the heart has spread – and is promoted in the marketing of the supplements – because the results from early trials suggested the capsules had cardiovascular benefits.Continue reading...
Source: Guardian Unlimited Science - July 17, 2018 Category: Science Authors: Sarah Boseley Health editor Tags: Health Medical research Food & drink Heart attack Stroke Science Life and style Society Source Type: news

What is the impact of user affect on motor learning in virtual environments after stroke? A scoping review
The purported affective impact of virtual reality (VR) and active video gaming (AVG) systems is a key marketing strategy underlying their use in stroke rehabilitation, yet little is known as to how affective c...
Source: Journal of NeuroEngineering and Rehabilitation - June 27, 2019 Category: Rehabilitation Authors: Nina Rohrbach, Emily Chicklis and Danielle Elaine Levac Tags: Review Source Type: research

FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz(R) IND for Stroke Treatment
FDA Responds to Company's IND #27375 Including Pharmacology, Manufacturing and Clinical Sections PHOENIX, May 14, 2021 -- (Healthcare Sales & Marketing Network) -- Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced t... Regenerative Medicine, Neurology, FDA Creative Medical Technology, ImmCelz, stroke
Source: HSMN NewsFeed - May 14, 2021 Category: Pharmaceuticals Source Type: news